Amyloid light chain (AL) amyloidosis is a rare but often fatal disease, with cardiomyopathy as a common initial presentation, and cardiac involvement being the strongest predictor of mortality. Due to its variable symptoms and perceived rarity, diagnosis is frequently delayed—often by up to two years—resulting in poor outcomes, especially since median survival for affected patients can be as short as four months. The lecture highlights the need for increased awareness, timely diagnosis, and emerging therapies—especially those combining targeted amyloid removal with existing treatments—for improving prognosis and patient outcomes.
Internationally renowned consultant hematologist, specializing in plasma cell disorders with a focus on monoclonal gammopathies of undetermined significance (MGUS), multiple myeloma, monoclonal gammopathy of renal significance (MGRS), and all types of amyloidosis.Â